Product/Composition:- | Metformin + Dapagliflozin Tablets |
---|---|
Strength:- | (dapagliflozin/metformin): 5 mg/500 mg, 5 mg/1000 mg, 10 mg/500 mg, 10 mg/1000 mg |
Form:- | Tablets |
Reference Brands:- | Xigduo XR®(US and EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Dapagliflozin/metformin (Xigduo XR) combines two mechanisms: dapagliflozin, an SGLT2 inhibitor, reduces blood glucose by increasing urinary glucose excretion, while metformin decreases hepatic glucose production and improves insulin sensitivity. Benefits include improved glycemic control, weight loss, and reduced cardiovascular risk in type 2 diabetes patients.
In the US, dapagliflozin/metformin (Xigduo XR) was approved by the FDA in February 2014 for type 2 diabetes as an adjunct to diet and exercise, with a warning to stop temporarily before surgery to reduce ketoacidosis risk. In the EU, Xigduo received marketing authorization in January 2014, and Ebymect in November 2015, for glycemic control in adults when metformin alone is inadequate. The EMA expanded metformin use in 2016 to patients with moderate kidney impairment (GFR 30–59 ml/min), with dose adjustments and monitoring for lactic acidosis. For sourcing, check Pharmatradz.com for supplier details and availability